Palifermin in a hematopoietic stem cell transplant patient with osteonecrosis of the jaw.
This case report describes the use of palifermin in a multiple myeloma patient with a history of osteonecrosis of the jaw (ONJ) for the prevention of high-dose chemotherapy-induced mucositis. Following the day of autologous stem cell infusion, palifermin was discontinued secondary to adverse events. Specifically, palifermin-associated macroglossia seemed to exacerbate the pain localized in the oral cavity area affected by ONJ, necessitating escalated doses of narcotic analgesics. When contemplating palifermin as a mucosal protectant in a hematopoietic stem cell transplant patient with ONJ, a careful benefit-to-risk assessment is in order to ensure optimal effectiveness without undue harm.
Yageman
Leah A
LA
Eugene Applebaum College of Pharmacy and Allied Health Professions, Wayne State University, Detroit, MI 48201-2020, USA.
Cronin
Simon M
SM
Peres
Edward
E
Abidi
Muneer H
MH
Ibrahim
Rami B
RB
D051523:Fibroblast Growth Factor 7 / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007568:Jaw; D052016:Mucositis / Q000139:chemically induced / Q000517:prevention & control; D009101:Multiple Myeloma / Q000150:complications / Q000628:therapy*; D010020:Osteonecrosis / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D019172:Transplantation Conditioning
D051523:Fibroblast Growth Factor 7